Across TCGA pan-cancer cohorts, ADAMTSL5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAMTSL5 data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher ADAMTSL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAMTSL5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BLCA, STAD, and HNSC are the cancer types where ADAMTSL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.153	0.720	<.001	45	view →
STAD	OS	Median	All	0.048	0.690	<.001	36	view →
HNSC	OS	Median	All	0.185	0.685	.036	9	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.220	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: ADAMTSL5 tumor-vs-normal RNA expression · all ADAMTSL5 data types